Sanofi (SNY)
After hours:
| Previous close | 49.71 |
| Open | 49.16 |
| Bid | 48.57 x 900 |
| Ask | 49.55 x 1300 |
| Day's range | 48.99 - 49.54 |
| 52-week range | 46.93 - 58.10 |
| Volume | |
| Avg. volume | 2,207,103 |
| Market cap | 124.319B |
| Beta (5Y monthly) | 0.36 |
| PE ratio (TTM) | 18.25 |
| EPS (TTM) | 2.69 |
| Earnings date | N/A |
| Forward dividend & yield | 1.75 (3.56%) |
| Ex-dividend date | 26 May 2022 |
| 1y target est | 69.00 |
- GlobeNewswire
Sanofi: Information concerning the total number of voting rights and shares – July 2022
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,534,952,234 €Registered office : 54, rue La Boétie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under n
- GlobeNewswire
Press Release: Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China
Sanofi and Innovent Biologics enter strategic collaboration to accelerate development of oncology medicines and expand presence in China Collaboration to accelerate the development and access of oncology medicines for cancer patients in ChinaClinical trial programs combining two of Sanofi’s prioritized oncology assets with sintilimab, the leading checkpoint inhibitor in China, to address some of the most prevalent solid tumors in China Sanofi to make an initial equity investment of €300 million
